Brainjo GmbH

Based in Germany, Brainjo GmbH specializes in developing virtual health solutions aimed at enhancing cognitive functions and promoting overall well-being for users through innovative digital applications and tools. Brainjo GmbH, founded in 2019 and headquartered in Regensburg, Germany, focuses on delivering health solutions through digital innovation. The company was established by Christian Gnerlich and Markus Wensauer. To date, Brainjo has successfully completed 3 deals, with its most recent funding round being a Seed round in February 2026, raising EUR 2 million led by High-Tech Gruenderfonds, alongside other investors such as MediVentures and NAVEC Investment Management.

The total amount raised by the company stands at EUR 2 million, with a current valuation of EUR 7. 075 million. Brainjo provides innovative health solutions aimed at enhancing cognitive function and overall well-being. The company's core offerings include a suite of digital applications and tools designed to support mental health and cognitive training.

These products focus on addressing specific use cases, such as stress management, memory enhancement, and mindfulness practices. They are marketed to various customer segments, including individuals seeking personal development and organizations aiming to promote employee wellness programs. Brainjo's products are available in multiple geographical markets, including North America and Europe, where they cater to a diverse clientele interested in personal health optimization. The revenue structure of Brainjo primarily revolves around a subscription-based model, allowing clients to access their suite of health solutions on a recurring basis.

Business transactions typically occur directly between Brainjo and its end users, with a focus on B2C engagement. This model is designed to foster long-term relationships with customers who benefit from ongoing access to the company’s flagship products. Specific pricing plans are structured to accommodate various user needs, ensuring that services remain accessible while generating steady revenue. The transaction framework emphasizes the value of continuous engagement, which is integral to Brainjo's business strategy.

In February 2026, Brainjo GmbH raised EUR 2 million in Seed funding to develop a next-generation prescribable virtual reality therapy designed specifically for children diagnosed with Attention Deficit Hyperactivity Disorder. The funding will enable the company to advance its product offerings while exploring new geographic markets for expansion. Brainjo aims to leverage these resources to enhance its presence in existing markets and to potentially enter new regions, improving access to its innovative health solutions.